Vir Biotechnology Inc expected to post a loss of 84 cents a share - Earnings Preview

Vir Biotechnology

05/05/2025 22:57

Vir Biotechnology Inc VIR.OQ VIR.O is expected to show a fall in quarterly revenue when it reports  results on May 7 for the period ending March 31 2025

The San Francisco California-based  company is expected to report a 84.8% decrease in revenue to $8.592 million from $56.38 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Vir Biotechnology Inc is for a loss of 84 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Vir Biotechnology Inc is $20.00​, above​ its last closing price of $6.16. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.87
-0.87
-0.76
Beat
12.9
Sep. 30 2024
-1.07
-1.05
-1.56
Missed
-48.2
Jun. 30 2024
-0.88
-0.90
-1.02
Missed
-13.9​
Mar. 31 2024
-1.06
-1.05
-0.48
Beat
54.3
​​Dec. 31 2023
-1.11
-1.01
-0.86
Beat
14.7
Sep. 30 2023
-1.25
-1.21
-1.22
Missed
-1.2​
Jun. 30 2023
-1.19
-1.20
-1.45
Missed
-20.5
Mar. 31 2023
-0.74
-0.87
-1.06
Missed
-21.2

This summary was machine generated May 5 at 21:57 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)